Other languages Biocon Limited

Equities

BIOCON

INE376G01013

Delayed NSE India S.E. Other stock markets 02:10:09 2024-05-29 am EDT			5-day change	1st Jan Change
316.8 ^INR	-0.30%		+2.87%	+26.90%

May. 24	INDIA STOCKS-Indian shares surrender gains as U.S. rate worries weigh	RE
May. 24	Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

INDIA STOCKS-Indian shares surrender gains as U.S. rate worries weigh	May. 24
Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea	May. 24
Biocon Limited Signs Exclusive Licensing and Supply Deal for the Commercialization of Liraglutide in South Korea with Handok Inc	May. 23
US FDA Approves Samsung Bioepis' Eye Disease Drug Opuviz	May. 23
Biocon's Consolidated Net Profit Declines in Fiscal Q4	May. 17
India's Biocon posts Q4 profit fall as higher raw material costs bite	May. 16
Biocon Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 16
Biocon Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 16
Biocon Signs Deal with Medix for Commercialization of Chronic Weight Management Drug in Mexico	May. 13
Biocon Limited Receives Approval from the South African Health Products Regulatory Authority for its Vertically Integrated, Complex Drug Product Tacrolimus Capsule 0.5mg, 1mg and 5mg Strengths, in South Africa	Apr. 20
India's Biocon developing its own version of Wegovy, clinical trial likely next year	Apr. 18
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	Apr. 17
Biocon Board to Consider Dividend for Fiscal 2024	Apr. 10
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	Apr. 02
Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution	Mar. 31
Biocon Limited to Obtain Approval for Diabetes Drug, Liraglutide, in the U.K	Mar. 27
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	Mar. 15
Biocon's CFO Resigns	Mar. 14
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	Mar. 14
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	Mar. 14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Biocon Limited

Equities

BIOCON

INE376G01013

Other languages

Filters